{"id":1739,"date":"2024-10-24T13:08:33","date_gmt":"2024-10-24T13:08:33","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T18:41:06","modified_gmt":"2026-06-26T18:41:06","slug":"epitopea-closes-usd-31-million-pre-series-a-financing","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/","title":{"rendered":"Epitopea Closes USD $31 million Pre-Series A Financing"},"content":{"rendered":"\n<p><strong>CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024<\/strong>&nbsp;&#8211; Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the closing of a USD $31 million pre-Series A financing.<\/p>\n\n\n\n<p>The pre-Series A financing brings the total capital raised by Epitopea to over USD $45 million. New investors Investissement Qu\u00e9bec, adMare BioInnovations and Jonathan Milner join existing investors Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarit\u00e9 FTQ, the Harrington Discovery Institute, IRICoR and Novateur Ventures, all of whom also participated in this financing round.<\/p>\n\n\n\n<p><strong>Dr. Alan C. Rigby, Epitopea\u2019s CEO<\/strong>&nbsp;said,&nbsp;<em>\u201cWe believe that more durable cancer therapies are needed to transform the lives of cancer patients diagnosed with hard-to-treat solid tumors where overall survival is still poor for most patients. We continue to make significant strides toward the clinic, which has strengthened investor enthusiasm, and resulted in an over-subscribed pre-Series A in support of our forward-looking mission and vision. This additional financing will support strategic pre-clinical discovery in solid tumors of interest while accelerating our near-term clinical development plans for Epitopea\u2019s next generation, tumor selective, off-the-shelf, RNA-based immunotherapies that we believe have the potential to extend the durability of clinical response in patients.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p><em>\u201cIn this round we would like to warmly welcome new investors Investissement Qu\u00e9bec, adMare BioInnovations and Jonathan Milner, whose participation complements the continued passionate support of our existing transatlantic investor syndicate. This pre-Series A raise provides the necessaryfinances to accelerate our development campaigns and transition to a clinical-stage company with a focused commitment of delivering our transformational RNA cancer immunotherapy into the clinic in 2026,\u201d<\/em>&nbsp;he added.<\/p>\n\n\n\n<p><strong>Satish Jindal, Ph.D., General Partner with Advent Life Sciences<\/strong>&nbsp;added,&nbsp;<em>\u201cAs a founding investor of Epitopea, we are pleased to continue our robust support of the company as it makes major strides in exploiting its proprietary CryptoMap<sup>TM<\/sup>&nbsp;platform to identify novel targets that can serve as the basis for the development of a range of ground-breaking cancer immunotherapies. Through our investment in this exciting and growing company, we look forward to Epitopea advancing a first off-the-shelf RNA cancer immunotherapy into the clinic, which could bring significant improvements to cancer patients\u2019 quality and duration of life.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cadMare is thrilled to invest in Epitopea and support the development of their highly differentiated RNA therapeutic platform. Epitopea\u2019s innovative approach to cancer treatment aligns with our mission to drive scientific progress and bring transformative therapies to patients. We look forward supporting the growth of this promising company,\u201d<\/em>&nbsp;said&nbsp;<strong>Fr\u00e9d\u00e9ric Lema\u00eetre Auger, Vice President Investments at adMare BioInnovations<\/strong>.<\/p>\n\n\n\n<p><em>\u201cAlongside other key players in the financial ecosystem, Investissement Qu\u00e9bec is proud to participate in this round of funding designed to accelerate preclinical stages and research into cancer immunotherapies. Our support will not only promote the development of homegrown expertise in Qu\u00e9bec, but also help drive the growth of a promising young Montr\u00e9al business at the heart of the strategic life-sciences sector\u201d<\/em>, said&nbsp;<strong>Bicha Ngo, President and CEO, Investissement Qu\u00e9bec.<\/strong><\/p>\n\n\n\n<p><br><strong>Contact information<\/strong><\/p>\n\n\n\n<p><strong>Epitopea<\/strong><br>Dr. Alan C. Rigby \u2013 CEO<br><a href=\"mailto:Alan.Rigby@epitopea.com\" target=\"_blank\" rel=\"noreferrer noopener\">Alan.Rigby@epitopea.com<\/a><br>Scius Communications<br><br><strong>Scius Communications<\/strong><br>Katja Stout<br>+44 7789 435990<br><a href=\"mailto:katja@sciuscommunications.com\">katja@sciuscommunications.com<\/a><br><br>Daniel Gooch<br>+44 7747 875479<br><a href=\"mailto:Daniel@sciuscommunications.com\">Daniel@sciuscommunications.com<\/a><\/p>\n\n\n\n<p><strong>About Epitopea<\/strong><\/p>\n\n\n\n<p>Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as Cryptigen<sup>TM<\/sup>&nbsp;TSAs, that are broadly shared across multiple patients with the same tumor type. The company has created an extensive library of novel Cryptigen<sup>TM&nbsp;<\/sup>TSAs, discovered by its proprietary CryptoMap<sup>TM<\/sup>&nbsp;platform that leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of aberrantly-expressed, tumour-specific antigens (aeTSA\u2019s) that are hidden within cancer\u2019s \u2019junk\u2019 DNA.&nbsp; These hidden Cryptigen<sup>TM<\/sup>&nbsp;TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Universit\u00e9 de Montr\u00e9al. Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarit\u00e9 FTQ, Investissement Qu\u00e9bec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures. To date the company has raised financing of more than USD $45 million. Epitopea was founded in 2021 and consists of sister companies based in Cambridge, UK and in Montreal, Canada. For additional information, please visit&nbsp;<a href=\"http:\/\/www.epitopea.com\/\">www.epitopea.com<\/a>&nbsp;and follow us on&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/epitopea\">LinkedIn<\/a>.<\/p>\n\n\n\n<p><strong>About Investissement Qu\u00e9bec<\/strong><\/p>\n\n\n\n<p>Investissement Qu\u00e9bec\u2019s mission is to play an active role in Quebec\u2019s economic development by stimulating business innovation, entrepreneurship, and business acquisitions, as well as growth in investment and exports. Operating in all the province\u2019s administrative regions, the Corporation supports the creation and growth of businesses of all sizes with investments and customized financial solutions. It also assists businesses by providing consulting services and other support measures, including technological assistance available from Investissement Qu\u00e9bec Innovation. In addition, through Investissement Qu\u00e9bec International, the Corporation prospects for talent and foreign investment, and assists Quebec businesses with export activities.<\/p>\n\n\n\n<p><strong>About adMare BioInnovations<\/strong><\/p>\n\n\n\n<p>With a strong track record of globally competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&amp;D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare has helped build 36 companies, of which 25 are still active. These companies have attracted $2.4&nbsp;billion of risk capital, have a combined value of $5.7&nbsp;billion, and have created around 1,000 jobs in Canada. Our dynamic Montreal and Vancouver Innovation Centers have been home to 48 life science companies&nbsp;to date, with the 27 current resident companies employing over 350 life sciences professionals. The adMare Academy has trained more than 750 alumni \u2014 92% of whom are employed in the life sciences industry. For more information, please visit&nbsp;<a href=\"https:\/\/www.admarebio.com\/en\/\">www.admarebio.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024&nbsp;&#8211; Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the closing of a USD $31 million pre-Series A financing. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1617,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[78],"class_list":["post-1739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Epitopea Closes USD $31 million Pre-Series A Financing | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epitopea Closes USD $31 million Pre-Series A Financing | adMare\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024&nbsp;&#8211; Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the closing of a USD $31 million pre-Series A financing. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-24T13:08:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T18:41:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Epitopea Closes USD $31 million Pre-Series A Financing\",\"datePublished\":\"2024-10-24T13:08:33+00:00\",\"dateModified\":\"2026-06-26T18:41:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/\"},\"wordCount\":1009,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/\",\"name\":\"Epitopea Closes USD $31 million Pre-Series A Financing | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"datePublished\":\"2024-10-24T13:08:33+00:00\",\"dateModified\":\"2026-06-26T18:41:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/epitopeanews-en-1739975092.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/epitopea-closes-usd-31-million-pre-series-a-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Epitopea Closes USD $31 million Pre-Series A Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epitopea Closes USD $31 million Pre-Series A Financing | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Epitopea Closes USD $31 million Pre-Series A Financing | adMare","og_description":"CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024&nbsp;&#8211; Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the closing of a USD $31 million pre-Series A financing. [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/","og_site_name":"adMare","article_published_time":"2024-10-24T13:08:33+00:00","article_modified_time":"2026-06-26T18:41:06+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Epitopea Closes USD $31 million Pre-Series A Financing","datePublished":"2024-10-24T13:08:33+00:00","dateModified":"2026-06-26T18:41:06+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/"},"wordCount":1009,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/","name":"Epitopea Closes USD $31 million Pre-Series A Financing | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","datePublished":"2024-10-24T13:08:33+00:00","dateModified":"2026-06-26T18:41:06+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/epitopeanews-en-1739975092.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/epitopea-closes-usd-31-million-pre-series-a-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Epitopea Closes USD $31 million Pre-Series A Financing"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1739"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1739\/revisions"}],"predecessor-version":[{"id":1740,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1739\/revisions\/1740"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1617"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1739"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}